Skip to main content
Interview with the Innovators
The Importance of Accurate Staging in Prostate Cancer
Dr Neal Shore emphasizes the importance of accurate staging of prostate cancer and how PYLARIFY® (piflufolastat F 18) can improve treatment decision-making in patients with prostate cancer. Read More ›

Use of PYLARIFY® in Specific Patient Groups
Dr Neal Shore highlights example patient populations that may benefit from improved staging through the use of PYLARIFY® (piflufolastat F 18), a prostate-specific membrane antigen (PSMA)-targeted PET/CT agent. Read More ›

PSMA PET Imaging in Patients with Oligometastatic Prostate Cancer
Dr Neal Shore discusses the importance of PSMA PET imaging across a range of PSA values and how PYLARIFY® (piflufolastat F 18) will affect imaging of patients with oligometastatic prostate cancer. Read More ›

PYLARIFY and Next-Generation Imaging
Dr Neal Shore elaborates on the ability of PYLARIFY® (piflufolastat F 18) to detect metastases and the practical aspects of next-generation imaging. Read More ›

PSMA-Targeted Imaging for Prostate Cancer Treatment
Dr Neal Shore discusses the rationale of prostate-specific membrane antigen (PSMA) PET/CT to guide prostate cancer treatment. Read More ›

Overview of Current Imaging Modalities in Prostate Cancer
Dr Neal Shore introduces the current global landscape of various imaging modalities for prostate cancer, including a new prostate-specific membrane antigen (PSMA)-targeted PET/CT agent, PYLARIFY® (piflufolastat F 18). Read More ›


Making a Difference with Early Identification and Treatment of Patients with NTRK Gene Fusions
Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, explain the benefits of testing for TRK fusion–positive tumors early for improved clinical outcomes. Read More ›

Real-World Management of Thyroid Cancer with TRK Inhibitors
Dr Ezra Cohen of UC San Diego, La Jolla, CA, and Dr Mary Fidler of Rush University Medical Center, Chicago, IL, recount their clinical experiences and the journeys of patients treated with TRK inhibitors for thyroid cancer. Read More ›

Real-World Experience with TRK Inhibitors in Patients with Lung and Colon Cancers
Dr Mary Fidler of Rush University Medical Center, Chicago, IL, and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, describe their practical experiences with TRK inhibitors in patients with lung cancer and colorectal cancer. Read More ›

Page 3 of 5